MICHAEL ITTMANN to Adenocarcinoma
This is a "connection" page, showing publications MICHAEL ITTMANN has written about Adenocarcinoma.
Connection Strength
1.366
-
Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. Prostate. 2006 Nov 01; 66(15):1641-52.
Score: 0.153
-
Systemic Ablation of Camkk2 Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer. Cells. 2022 06 10; 11(12).
Score: 0.113
-
Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999 May; 5(5):1063-71.
Score: 0.091
-
Chromosome 10 alterations in prostate adenocarcinoma (review). Oncol Rep. 1998 Nov-Dec; 5(6):1329-35.
Score: 0.088
-
Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. Nat Commun. 2018 10 04; 9(1):4080.
Score: 0.088
-
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res. 1998 Mar; 4(3):811-5.
Score: 0.084
-
SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. Oncogene. 2017 08 17; 36(33):4767-4777.
Score: 0.079
-
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Rep. 2016 Feb 02; 14(4):907-919.
Score: 0.073
-
Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol. 1996 Jan; 27(1):28-34.
Score: 0.072
-
Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. Horm Cancer. 2015 Jun; 6(2-3):67-86.
Score: 0.068
-
Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol. 1994 Aug; 145(2):287-93.
Score: 0.066
-
The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. Cancer Res. 2013 Jul 01; 73(13):3997-4008.
Score: 0.060
-
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013 May 01; 73(9):2718-36.
Score: 0.060
-
Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
Score: 0.051
-
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010 Jul; 184(1):149-56.
Score: 0.049
-
Relaxin promotes prostate cancer progression. Clin Cancer Res. 2007 Mar 15; 13(6):1695-702.
Score: 0.039
-
Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res. 2003 Oct 01; 63(19):6237-43.
Score: 0.031
-
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 2003 May 15; 55(3):219-37.
Score: 0.030
-
Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol. 1998 Feb; 159(2):471-5; discussion 475-6.
Score: 0.021
-
GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. Oncotarget. 2016 Jul 19; 7(29):45171-45185.
Score: 0.019
-
Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells. PLoS One. 2014; 9(9):e106289.
Score: 0.016
-
FGFR1-WNT-TGF-? signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014 Jan 15; 74(2):609-20.
Score: 0.016